New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Cardio Diagnostics Holdings, Inc. (CDIO) vs Lantern Pharma Inc. (LTRN)

Cardio Diagnostics Holdings, Inc. and Lantern Pharma Inc. are both Biotechnology companies. Cardio Diagnostics Holdings, Inc. and Lantern Pharma Inc. are of similar size ($4.9M and $4.9M). Lantern Pharma Inc. has the higher net margin (0.00% vs −42,401.3%) and the higher return on invested capital (0.00% vs −228.0%). Across the 13 metrics below, Cardio Diagnostics Holdings, Inc. leads on 8 and Lantern Pharma Inc. on 5.

Valuation

Metric CDIO LTRN Biotechnology median
P/E n/m n/m 8.26
P/S 319.11 n/m 9.20
P/B 0.85 2.68 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA n/m 0.22 0.67
EV/Sales 61.40 n/m 9.05
Earnings yield (153.33%) (420.86%) (34.24%)
Free cash flow yield (118.47%) (339.75%) (24.77%)

Profitability

Metric CDIO LTRN Biotechnology median
Gross margin 100.00% 0.00% 70.18%
Operating margin (42,328.76%) 0.00% 0.00%
Net margin (42,401.31%) 0.00% 0.00%
Free cash flow margin (37,804.58%) 0.00% 0.00%
Return on equity (93.55%) (250.59%) (51.58%)
Return on assets (87.24%) (124.41%) (45.91%)
Return on invested capital (227.99%) 0.00% 0.00%

Growth

Metric CDIO LTRN Biotechnology median
Revenue growth (TTM) (3.16%) — 7.20%
EPS growth (last fiscal year) 60.15% 18.65% 29.04%
Revenue growth, 5-year CAGR — — 9.48%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CDIO LTRN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 17.44 1.49 4.83
Net debt to EBITDA 0.84 0.56 1.01

Dividend

Metric CDIO LTRN Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric CDIO LTRN Biotechnology median
Market cap 4.88m 4.92m 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack